Richard A. Morgan

16.5k total citations · 4 hit papers
112 papers, 7.4k citations indexed

About

Richard A. Morgan is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Richard A. Morgan has authored 112 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 59 papers in Genetics and 48 papers in Molecular Biology. Recurrent topics in Richard A. Morgan's work include Virus-based gene therapy research (59 papers), CAR-T cell therapy research (59 papers) and CRISPR and Genetic Engineering (21 papers). Richard A. Morgan is often cited by papers focused on Virus-based gene therapy research (59 papers), CAR-T cell therapy research (59 papers) and CRISPR and Genetic Engineering (21 papers). Richard A. Morgan collaborates with scholars based in United States, United Kingdom and Israel. Richard A. Morgan's co-authors include Steven A. Rosenberg, Zhili Zheng, Nicholas P. Restifo, Steven A. Feldman, Yangbing Zhao, Paul F. Robbins, W. French Anderson, Mark E. Dudley, Barbara Ensoli and Robert C. Gallo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Annual Review of Biochemistry.

In The Last Decade

Richard A. Morgan

110 papers receiving 7.3k citations

Hit Papers

Release, uptake, and effects of extracellular human immun... 1993 2026 2004 2015 1993 2014 2012 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
    1993 694 citations Richard A. Morgan, Robert C. Gallo et al. profile →
  2. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
  3. Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
    2012 380 citations Richard A. Morgan, Christopher L. Wolfgang et al. profile →
  4. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
    2019 301 citations Richard A. Morgan, Richard M. Sherry et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard A. Morgan United States 44 4.8k 2.8k 2.7k 2.5k 877 112 7.4k
Rimas J. Orentas United States 34 6.6k 1.4× 2.9k 1.0× 2.2k 0.8× 2.0k 0.8× 1.9k 2.2× 120 8.2k
Yolanda D. Mahnke United States 19 4.4k 0.9× 2.6k 0.9× 1.7k 0.6× 1.2k 0.5× 1.1k 1.3× 32 6.4k
Cassian Yee United States 51 6.4k 1.3× 7.6k 2.7× 2.9k 1.1× 1.1k 0.5× 551 0.6× 156 11.6k
Zhili Zheng United States 43 7.8k 1.6× 5.8k 2.1× 3.1k 1.2× 2.5k 1.0× 1.0k 1.2× 68 10.0k
J. Fraser Wright United States 40 3.3k 0.7× 1.4k 0.5× 4.4k 1.7× 3.8k 1.5× 759 0.9× 89 7.9k
Chiara Bonini Italy 48 5.8k 1.2× 4.0k 1.4× 3.6k 1.4× 3.3k 1.3× 1.1k 1.3× 180 10.7k
Catherine M. Bollard United States 57 8.1k 1.7× 5.5k 1.9× 1.7k 0.7× 2.9k 1.2× 926 1.1× 367 12.6k
Carmine Carpenito United States 22 4.3k 0.9× 2.8k 1.0× 1.6k 0.6× 1.4k 0.6× 1.2k 1.4× 37 5.8k
Ann M. Leen United States 46 4.9k 1.0× 2.8k 1.0× 1.3k 0.5× 2.5k 1.0× 689 0.8× 165 7.2k
John Scholler United States 29 5.5k 1.1× 2.6k 0.9× 2.3k 0.9× 1.7k 0.7× 1.7k 1.9× 68 7.0k

Countries citing papers authored by Richard A. Morgan

Since Specialization
Citations

This map shows the geographic impact of Richard A. Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Morgan more than expected).

Fields of papers citing papers by Richard A. Morgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Morgan. The network helps show where Richard A. Morgan may publish in the future.

Co-authorship network of co-authors of Richard A. Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Morgan. A scholar is included among the top collaborators of Richard A. Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Morgan. Richard A. Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Young, David J., So Gun Hong, Jacob Turner, et al.. (2024). In vivo tracking of ex-vivo-generated 89Zr-oxine-labeled plasma cells by PET in a non-human primate model. Molecular Therapy. 33(2). 580–594. 4 indexed citations
2.
Wong, Ryan L., Devin Brown, Shantha Senadheera, et al.. (2022). Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenousCYBBregulation and expression. Blood. 141(9). 1007–1022. 11 indexed citations
3.
4.
5.
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →
6.
Morgan, Richard A. & Sunitha Kakarla. (2014). Genetic Modification of T Cells. The Cancer Journal. 20(2). 145–150. 11 indexed citations
7.
Chinnasamy, Dhanalakshmi, Eric Tran, Zhiya Yu, et al.. (2013). Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice. Cancer Research. 73(11). 3371–3380. 90 indexed citations
8.
Morgan, Richard A.. (2013). Revision to Australian standard AS4324.1-1995 for materials handling of bulk products. 564. 1 indexed citations
9.
Fu, Tao, Emmanouil P. Pappou, Angela A. Guzzetta, et al.. (2012). CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis. Clinical Cancer Research. 18(17). 4743–4752. 41 indexed citations
10.
Morgan, Richard A., Laura A. Johnson, Jeremy L. Davis, et al.. (2012). Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma. Human Gene Therapy. 23(10). 1043–1053. 246 indexed citations
11.
Davis, Jeremy L., Marc R. Theoret, Zhili Zheng, et al.. (2010). Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials. Clinical Cancer Research. 16(23). 5852–5861. 94 indexed citations
12.
Frankel, Timothy L., William R. Burns, Peter D. Peng, et al.. (2010). Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase. The Journal of Immunology. 184(11). 5988–5998. 60 indexed citations
13.
Horovitz‐Fried, Miryam, et al.. (2010). Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition. The Journal of Immunology. 184(11). 6232–6241. 64 indexed citations
14.
Chinnasamy, Nachimuthu, Jennifer A. Wargo, Zhiya Yu, et al.. (2010). A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer. The Journal of Immunology. 186(2). 685–696. 130 indexed citations
15.
Nordon, Ian M., et al.. (2009). EVAR for ruptured AAAs -- Do we need randomized controlled trials?. PubMed. 50(5). 617–25. 1 indexed citations
16.
Zhao, Yangbing, Alan Bennett, Zhili Zheng, et al.. (2007). High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines. The Journal of Immunology. 179(9). 5845–5854. 164 indexed citations
17.
Morgan, Richard A., Mark E. Dudley, Yik Y. L. Yu, et al.. (2003). High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. The Journal of Immunology. 171(6). 3287–3295. 175 indexed citations
18.
19.
Morgan, Richard A., et al.. (1994). Further Evaluation of Soluble CD4 as an Anti-HIV Type 1 Gene Therapy: Demonstration of Protection of Primary Human Peripheral Blood Lymphocytes from Infection by HIV Type 1. AIDS Research and Human Retroviruses. 10(11). 1507–1515. 28 indexed citations
20.
Morgan, Richard A., Kenneth Cornetta, & W. French Anderson. (1990). Applications of the Polymerase Chain Reaction in Retroviral-Mediated Gene Transfer and the Analysis of Gene-Marked Human TIL Cells. Human Gene Therapy. 1(2). 135–149. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rimas J. Orentas Breakdown of academic impact, for papers by Yolanda D. Mahnke Breakdown of academic impact, for papers by Cassian Yee Breakdown of academic impact, for papers by Zhili Zheng Breakdown of academic impact, for papers by J. Fraser Wright Breakdown of academic impact, for papers by Chiara Bonini Breakdown of academic impact, for papers by Catherine M. Bollard Breakdown of academic impact, for papers by Carmine Carpenito Breakdown of academic impact, for papers by Ann M. Leen Breakdown of academic impact, for papers by John Scholler
Rankless by CCL
2026